DEDAGROUP-STEALTH
Dedagroup Stealth, the tech company behind more than 60% of Italy’s best-known global fashion brands, has acquired Zedonk, the company relied on by more than 650 small fashion businesses.
Until now, smaller brands and start-ups had no access to a single, integrated solution for managing the entire product life cycle, from initial design and production, right through to multichannel distribution in retail, wholesale, marketplaces and social commerce channels, and in addition they had no access to an Enterprise Resource Planning (ERP) technology to support rapid international growth. The acquisition of Zedonk by Dedagroup Stealth fills this market gap.
Dedagroup Stealth is one of only a handful of international companies with a wide range of software solutions for the efficient and flexible management of all the production and distribution processes for fashion products across multiple channels, which has given it leadership among large and medium-sized brands.
Now, with Zedonk, Dedagroup Stealth will be a unique partner for smaller fashion companies, from the very beginning of their growth trajectory right through to international expansion.
Zedonk enables brands in their emerging phase as well as those who are established, but want to accelerate their digital transformation journeys. Its solutions include design and production management, stock inventory, purchase orders, style management as well as customer and supplier relations, with all data managed and protected in the Cloud.
As well as complementary technologies, the two companies now have a significant footprint in the UK through new headquarters in London where Dedagroup Stealth consultants already on the ground will join the Zedonk team.
Marcia Lazar, Co-founder of Zedonk , said: "We join the Dedagroup Stealth family with great enthusiasm. For us, it is the ideal strategic partner to continue on our ambitious development path. We are truly satisfied with this global operation, which has the clear objective of bringing to the fashion sector an offer that can accompany any brand in every phase of its life, from the launch to the intermediate development phase up to maturity, supporting it in the definition of processes and strategies.”
Mimmo Solida, CEO of Dedagroup Stealth , added: “For too long, many brands have struggled to find an integrated solution that helps them manage their entire supply chain. It has long been our ambition to find a partner that can support designers, small brands and fashion start-ups as they grow, with a range of solutions that support business critical focuses of fashion retailers, from supply chain to sales, that allow for internationalisation. This acquisition will bring new value to the market and, at the same time, will strongly support our expansion strategy geographically and as a business, whilst completing our product portfolio to support fashion brands from entrepreneurial start-ups to enterprise players.”
Marco Podini, Executive Chairman of Dedagroup Stealth parent company Dedagroup, commented: "I am particularly pleased by the acquisition of Zedonk because our software, which has already contributed to the growth of many important creative brands in the world, can help other small fashion companies to develop rapidly. Our support is more vital than ever now that the market has changed so drastically for companies of all sizes, made even worse in the current crisis as whole countries shut down.”
“The global fashion industry needs the right tools to capitalise on business opportunities without being overwhelmed at an organisational level. The tsunami moving from east to west, leaving behind lowered shutters and people locked indoors, will be followed by a second wave that will see everyone wanting to get back to normal. Agility, underpinned by robust digital technologies, will be the catalyst that defines business success and will fuel retail performance in markets as they reopen, starting from China. Dedagroup Stealth will be able to support brands from the very smallest up to the largest as they restart their plans for global expansion,” Podini concluded.
-ENDS-
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005645/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
